Livanova Plc (LIVN) Stock Price & Analysis
Livanova Plc (LIVN) fell 0.53% to USD 78.19 as of July 25, 2026 at 03:02 UTC, according to Nexqual real-time market data.
LIVN last closed at USD 78.61; the session ranged USD 77.86–79.61 on volume of 396,059 shares. Market capitalization is $4.30B, with a 52-week range of USD 41.02–85.27 (NMS). Source: Nexqual, July 25, 2026 at 03:02 UTC.
Key Statistics (as of July 25, 2026 at 03:02 UTC)
| Price | USD 78.19 |
|---|---|
| Change | ▼ 0.53% (down) |
| Previous Close | USD 78.61 |
| Open | USD 79.61 |
| Day Range | USD 77.86 – 79.61 |
| 52-Week Range | USD 41.02 – 85.27 |
| Volume | 396,059 shares |
| Market Cap | $4.30B |
| Exchange | NMS |
Technical Analysis (LIVN)
Nexqual's technical model rates LIVN "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 03:02 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 47.62 (neutral) |
| vs SMA50 | Above (USD 77.87) |
| MACD | 0.19 (positive) |
Analyst Ratings (LIVN)
Wall Street analysts rate LIVN "Buy" based on 10 analysts, with a mean price target of USD 84.8 (range USD 67–95), per Nexqual as of July 25, 2026 at 03:02 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 84.8 |
| High Target | USD 95 |
| Low Target | USD 67 |
| Buy / Hold / Sell | 8 / 1 / 1 |
Earnings (LIVN)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 1.09 |
| Revenue Estimate | $380.58M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.98 vs est 0.9 ▲ beat |
| 2025-12-31 | USD 0.86 vs est 0.81 ▲ beat |
| 2025-09-30 | USD 1.11 vs est 0.92 ▲ beat |
| 2025-06-30 | USD 1.05 vs est 0.87 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:02 UTC.
Financials & Fundamentals (LIVN)
| Total Revenue | $1.43B |
|---|---|
| Revenue Growth (YoY) | +14.30% |
| Gross Margin | +67.86% |
| Operating Margin | +14.39% |
| Profit Margin | +7.47% |
| ROE | +9.54% |
| Debt / Equity | 28.35 |
| Current Ratio | 1.33 |
| Total Cash | $539.71M |
| Total Debt | $343.44M |
| Free Cash Flow | $198.05M |
Source: Nexqual, July 25, 2026 at 03:02 UTC.
Financial Health Score (LIVN)
Nexqual rates Livanova Plc's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 03:02 UTC.
| Growth | Solid — Revenue +11% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 68%, operating 14% |
| Balance Sheet | Strong — $540M cash vs $343M debt, net cash position |
| Cash Flow | Solid — FCF $198M, 14% margin |
| Efficiency | Mixed — ROE 10%, ROA 5.3% |
Ownership (LIVN)
| Insider Ownership | +0.42% |
|---|---|
| Institutional Ownership | +112.92% |
| Shares Outstanding | 54.93M |
| Float | 54.65M |
| Short % of Float | +8.24% |
Source: Nexqual, July 25, 2026 at 03:02 UTC.
Leadership (LIVN)
Livanova Plc is led by Vladimir A. Makatsaria (age 52), CEO & Director, per Nexqual as of July 25, 2026 at 03:02 UTC.
| CEO & Director | Vladimir A. Makatsaria (age 52) |
|---|---|
| Chief Financial Officer | Alex Shvartsburg C.M.A. (age 55) |
| Vice President of Investor Relations | Briana Gotlin |
| Vice President of Corporate Communications | Deanna Wilke |
| Chief Strategy & Corporate Development Officer | Philip Kowalczyk |
Major Backers & Investors (LIVN)
Notable institutional backers of Livanova Plc include Primecap Management Company, Artisan Partners Limited Partnership, American Century Companies Inc, according to Nexqual as of July 25, 2026 at 03:02 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Primecap Management Company | 7.66% |
| Artisan Partners Limited Partnership | 6.26% |
| American Century Companies Inc | 6.21% |
| FMR, LLC | 4.85% |
| AQR Capital Management, LLC | 4.54% |
| Millennium Management | 4.44% |
| Wellington Management | 3.44% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 18.75% |
| State Street | 3.77% |
| Vanguard Group | 3.48% |
Source: Nexqual, July 25, 2026 at 03:02 UTC.
From Livanova Plc's Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services.
- The company operates in two segments, Cardiopulmonary and Neuromodulation.
- The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products.
- The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ITGR | Integer Holdings Corporation | USD 98.62 | ▲ 2.13% |
| CNMD | CONMED Corporation | USD 42.68 | ▲ 1.62% |
| SGRY | Surgery Partners, Inc. | USD 15.73 | ▲ 3.83% |
| ICUI | ICU Medical, Inc. | USD 157.44 | ▲ 0% |
| VREX | Varex Imaging Corporation | USD 10.92 | ▲ 2.44% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:02 UTC. This page is informational and not investment advice.